D. Boral Capital downgraded Enlivex Therapeutics (ENLV) to Hold from Buy with no price target after the company announced a $212M private placement for 212M shares priced at $1.00 to initiate a digital asset treasury strategy centered on the accumulation of RAIN tokens designed for on-chain predictive markets, options trading, and transparent data aggregation. The firm, which notes its valuation models had been based on the value of the therapeutic, says those are “less relevant now” and it needs some time to understand how to value the company following the shift.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ENLV:
- Enlivex Therapeutics prices 212M shares at $1.00 in private placement
- Enlivex Therapeutics announces topline data from Phase I/II trial of Allocetra
- Enlivex Reports Q3 2025 Financial Results Amidst Operational Challenges
- Enlivex Reschedules Annual Meeting Due to Lack of Quorum
- Enlivex Therapeutics Advances Psoriatic Arthritis Treatment with Allocetra Study